Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Sandoz | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Mexico | es
  • United States | en
  • Australia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Saudi Arabia | ar
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Sandoz

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Saudi Arabia | ar
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About Sandoz 
      • Our Purpose and Ambition 
      • What We Do 
      • Innovation, Quality and Supply 
      • Corporate Responsibility 
        • Ethics, Risk and Compliance 
        • Sandoz external funding 
        • Malaria Initiative 
        • Novartis Access 
        • World Child Cancer 
      • Our History 
      • Investor Information 
      A girl with a flower About Sandoz
    • Products & Services 
      • Disease Areas 
        • Anti-Infectives 
        • Respiratory 
        • Endocrinology 
        • Immunology 
        • Oncology 
      • Biopharmaceuticals 
        • Sandoz Biosimilars 
        • Sandoz Biosimilar Portfolio and Pipeline 
        • About Biologics 
        • Development of Biosimilars 
        • Information for Patients 
      • Prescription Medicines 
      • Over-The-Counter Medicines 
      • Partnerships and Collaborations 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
      00181_300dpi_RGB Products & Services
    • People & Culture 
      • Sandoz Leadership 
        • Richard Saynor 
        • Francisco Ballester 
        • Martin Bischof 
        • Colin Bond 
        • Pierre Bourdage 
        • Valerie Chew 
        • Claire D'Abreu-Hayling 
        • Glenn A. Gerecke, PhD 
        • Rebecca Guntern 
        • Keren Haruvi 
        • Steffen Kurzawa 
        • Inge Maes 
        • Ingrid Sollerer 
      • Diversity & Inclusion 
      • Associate Stories 
    • Investors & Media 
      • Sandoz spin-off 
      • Media Releases 
      • Media Library 
      • Media Contacts 
      • Novartis Annual Reporting Suite 
    • Careers 
      • Working at Sandoz 
      • Diversity & Inclusion 
      • Associate Stories 
      • Job Search 
      Sandoz Careers Careers
    • News 
      • News Archive 
      • Media Releases 
      • Publications 
      • Stay Up-To-Date 
      A photo of people in a meeting hall News
    • Contacts 
    working at sandoz Home
  1. Home
  2. News
  3. All News
News Archive Navigation
  • All
  • Featured News
  • Media Release
icon
News Archive Navigation Language
  • English
  • French
  • German

July 2020

  • Media ReleaseJul 07, 2020
    Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals
    Sandoz to provide six injectable medicines used in acute care settings to help ensure supply reliability for optimal patient care Securing reliable supply of and access to these high-quality…
  • Media ReleaseJul 01, 2020
    Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case
    Sandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic…

June 2020

  • Media ReleaseJun 19, 2020
    Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
    Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
  • Media ReleaseJun 04, 2020
    Sandoz launches once-daily generic tacrolimus for transplant patients in Europe
    Sandoz is first and only company offering complete range of dosing options in several European markets*, with 2 mg capsule allowing for fine dose titration Sandoz 2 mg slow-release capsule offers…

April 2020

  • Media ReleaseApr 28, 2020
    Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
    Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569 million (+62% cc…
  • Media ReleaseApr 20, 2020
    Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
    Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
  • Media ReleaseApr 02, 2020
    Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
    Basel, April 1, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…

March 2020

  • Media ReleaseMar 30, 2020
    Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
    Princeton - Novartis announced today that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of…
  • Media ReleaseMar 25, 2020
    Sandoz announces new country head for Japan
    Shingo Iwamoto appointed country head for Sandoz in Japan Shingo Iwamoto will also oversee Japanese business of Aspen Global Incorporated (AGI), successfully acquired by Sandoz on February 1 this…
  • Media ReleaseMar 20, 2020
    Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
    Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory…
  • Media ReleaseMar 02, 2020
    Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
    Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…

February 2020

  • Media ReleaseFeb 26, 2020
    Sandoz commits to keep prices stable for basket of essential COVID-19 medicines; Novartis responds to COVID-19 with broad range of initiatives
    Sandoz, a global generics leader and the #1 provider of off-patent antibiotic medicines worldwide, is making a public commitment to ensure stable pricing for a basket of essential medicines the…

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • › Next page

Sandoz Global

Key resources
  • Patients & Caregivers
  • Job seekers
  • Investors
  • Media
Recent updates
  • Sandoz spin-off
Explore
  • Contacts
  • Locations
  • Biosimilar Portfolio and Pipeline
Sandoz Companies
  • 1A Pharma
  • Hexal
  • Lek
Footer Bottom
© 2023 Sandoz International GmbH
  • Terms of Use
  • Privacy Policy
  • About Cookies
  • Legal Notice
  • Social Media Community Guidelines
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for a global audience